Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Clarus Therapeutics files to sell 1.3M shares of common stock for holders  17:29
05/24/22
05/24
17:29
05/24/22
17:29
CRXT

Clarus Therapeutics

/

+

 
ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

05/17/22 Truist
Clarus Therapeutics price target lowered to $3 from $7 at Truist
03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
CRXT Clarus Therapeutics
/

+

Hot Stocks
Clarus Therapeutics announces issuance of patent covering JATENZO » 09:11
05/18/22
05/18
09:11
05/18/22
09:11
CRXT

Clarus Therapeutics

/

+

Clarus Therapeutics…

Clarus Therapeutics announced that the United States Patent and Trademark Office has issued a new patent for claims that cover Clarus' oral testosterone replacement product, JATENZO. Patent No. 11,331,325 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" covers Clarus' commercialized product, JATENZO. The new patent will expire in January 2027. "This new patent further reinforces our already impressive intellectual property portfolio for JATENZO," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "We believe that having eight patents listed in FDA's Orange Book underscores our multi-pronged strategy for success in the marketplace by protecting this important asset."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

05/17/22 Truist
Clarus Therapeutics price target lowered to $3 from $7 at Truist
03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
CRXT Clarus Therapeutics
/

+

Recommendations
Clarus Therapeutics price target lowered to $3 from $7 at Truist » 07:47
05/17/22
05/17
07:47
05/17/22
07:47
CRXT

Clarus Therapeutics

/

+

Truist analyst Gregory…

Truist analyst Gregory Fraser lowered the firm's price target on Clarus Therapeutics to $3 from $7 but keeps a Buy rating on the shares. The company's Q1 Jatenzo sales came in just below estimates, and while it has gained some runway with the recent financing, it will need additional capital in the coming months, the analyst tells investors in a research note. Fraser adds that he remains optimistic about the potential of Jatenzo in the large testosterone market.

ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
CRXT Clarus Therapeutics
/

+

Hot Stocks
Clarus announces notice of allowance from USPTO for claims covering CLAR-121 » 09:14
05/10/22
05/10
09:14
05/10/22
09:14
CRXT

Clarus Therapeutics

/

+

Clarus Therapeutics…

Clarus Therapeutics announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, for claims that cover certain methods for the treatment of autoimmune inflammatory mastitis that can be achieved by its product candidate, CLAR-121, a proprietary combination of testosterone and anastrozole delivered by a subcutaneous implant. Patent application No. 17/437,525 is entitled "Pharmaceutical Formulations and Systems for Delivery of an Androgenic Agent and an Aromatase Inhibitor with Sustained Multi-Phasic Release Profiles and Methods of Use." The U.S. patent scheduled to issue from this application will expire in June 2040. "We are thrilled to further establish intellectual property protection for our pipeline," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "We believe this notice of allowance validates the innovation behind CLAR-121 and supports this novel approach for treating androgen-mediated inflammatory breast diseases. Our initial focus for CLAR-121 will be for the treatment of PDM, a painful condition of inflamed breast tissue that predominantly affects women and for which there is currently no available drug interventions. We are currently seeking Orphan Drug Designation from the FDA for CLAR-121 for the treatment of PDM in the second quarter of 2022 and anticipate initiating a Phase 2 clinical trial in the second half of 2022."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
CRXT Clarus Therapeutics
/

+

Hot Stocks
Clarus announces notice of allowance from USPTO for patent covering JATENZO » 09:12
04/28/22
04/28
09:12
04/28/22
09:12
CRXT

Clarus Therapeutics

/

+

Clarus Therapeutics…

Clarus Therapeutics announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO for claims that cover its oral testosterone replacement product, JATENZO. Patent application No. 16/656,178 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" covers Clarus' commercialized product, JATENZO. The U.S. patent scheduled to issue from this application will expire in 2026. "As we continue to grow the JATENZO brand, we are extremely pleased that we can further reinforce its robust intellectual property portfolio," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "Once issued, this new patent will be listed in FDA's Orange Book, thus bringing the total number of patents covering JATENZO in the United States to eight."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
CRXT Clarus Therapeutics
/

+

Syndicate
Clarus Therapeutics announces pricing of $30M underwritten public offering » 10:55
04/25/22
04/25
10:55
04/25/22
10:55
CRXT

Clarus Therapeutics

$1.80 /

-0.51 (-22.08%)

Clarus Therapeutics…

Clarus Therapeutics announced the pricing of its underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock is being sold together with one Class A warrant at a combined purchase price of $1.10 per unit. Clarus also granted the underwriter an option to purchase up to an additional 4,090,608 shares of common stock and/or Class A warrants to purchase up to 4,090,608 shares of common stock. The Class A warrants will be immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock and accompanying Class A warrants can only be purchased together in the offering, but will be issued separately and will be immediately separable upon issuance. The pre-funded warrants and the Class A warrants will not be listed on any exchange. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding the proceeds from the exercise of any Class A warrants and the exercise of the underwriter's overallotment option, are expected to be approximately $30M. The offering is expected to close on April 27, 2022, subject to customary closing conditions. Clarus expects to use the net proceeds from the offering, together with its existing cash, for working capital and other general corporate purposes. Maxim Group LLC is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
CRXT Clarus Therapeutics
$1.80 /

-0.51 (-22.08%)

CRXT Clarus Therapeutics
$1.80 /

-0.51 (-22.08%)

03/31/22 Needham
Clarus Therapeutics price target lowered to $8 from $12 at Needham
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
CRXT Clarus Therapeutics
$1.80 /

-0.51 (-22.08%)

Over a quarter ago
Recommendations
Clarus Therapeutics price target lowered to $8 from $12 at Needham » 08:12
03/31/22
03/31
08:12
03/31/22
08:12
CRXT

Clarus Therapeutics

$2.07 /

+0.18 (+9.52%)

Needham analyst Serge…

Needham analyst Serge Belanger lowered the firm's price target on Clarus Therapeutics to $8 from $12 but keeps a Buy rating on the shares after its Q4 results. The price target change reflects a slower Jatenzo sales growth trajectory than previously expected, though 11 weeks into Q1, the company's RXs are up 9% vs. Q4 levels and have been accelerating in recent weeks, the analyst tells investors in a research note. The main near-term focus is to address Clarus's financing needs given the very limited current runway, Belanger adds.

ShowHide Related Items >><<
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
09/29/21 Maxim
Clarus Therapeutics initiated with a Buy at Maxim
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

Hot Stocks
Clarus Therapeutics says continuing to explore strategic alternatives » 16:20
03/30/22
03/30
16:20
03/30/22
16:20
CRXT

Clarus Therapeutics

$2.07 /

+0.18 (+9.52%)

The company said,…

The company said, "Our cash and cash equivalents as of December 31, 2021 will fund our current operating plan into approximately April 2022. Accordingly, we continue to explore strategic alternatives for the purpose of maximizing stockholder value and expect to devote significant efforts to raise capital, restructure our indebtedness and identify and evaluate potential strategic alternatives. There can be no assurance that these efforts will be successful, and our board of directors is assessing appropriate alternatives available to Clarus. Any failure in these efforts could force us to delay, limit or terminate our operations, make reductions in our workforce, discontinue our commercialization efforts for JATENZO as well as other development programs, liquidate all or a portion of our assets or pursue other strategic alternatives, and/or seek protection under the provisions of the U.S. Bankruptcy Code."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
09/29/21 Maxim
Clarus Therapeutics initiated with a Buy at Maxim
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

Earnings
Clarus Therapeutics reports Q4 EPS (19c), consensus (68c) » 16:19
03/30/22
03/30
16:19
03/30/22
16:19
CRXT

Clarus Therapeutics

$2.07 /

+0.18 (+9.52%)

Reports Q4 revenue…

Reports Q4 revenue $4.56M, consensus $4.64M. "Clarus delivered solid growth in net revenue as a new public company driven by continued demand for JATENZO," said Robert Dudley, president and CEO of Clarus. "We also significantly expanded payer access coverage for JATENZO as payers recognized its value and innovation for treatment of appropriate hypogonadal men. In February, we launched our new online patient portal, partnering with Vault Health and AssistRx, leaders in providing healthcare services to patients. We believe our commitment to serve patients through these partnerships will enhance overall patient experiences and positively impact JATENZO sales. We are excited that JATENZO continues to perform well in the market. We continue to explore various financing and strategic options to maximize stockholder value. We thank our stockholders for their continued support and our employees for their dedication and hard work."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
09/29/21 Maxim
Clarus Therapeutics initiated with a Buy at Maxim
CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

CRXT Clarus Therapeutics
$2.07 /

+0.18 (+9.52%)

Hot Stocks
Clarus Therapeutics announces initiation of Phase 4 clinical trial of JATENZO » 09:16
03/16/22
03/16
09:16
03/16/22
09:16
CRXT

Clarus Therapeutics

/

+

Clarus Therapeutics…

Clarus Therapeutics announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO oral softgel capsules for the treatment of adult hypogonadal men with chronic kidney disease, CKD. Clarus expects to announce results from the trial in the first half of 2023. "We are excited screening has begun for the first patient in this trial of hypogonadal men with CKD," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "Patients with CKD suffer from a myriad of comorbidities, which often include profound reductions in circulating T. Epidemiological data indicate that an estimated two million men with CKD are clinically hypogonadal and thus may benefit from T replacement therapy. This will be the first of several life cycle management studies for JATENZO designed to maximize the potential for treatment of specific patient populations where T deficiency is a component of their compromised health."

ShowHide Related Items >><<
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/13/21 Truist
Clarus Therapeutics initiated with a Buy at Truist
10/06/21 Needham
Clarus Therapeutics initiated with a Buy at Needham
09/29/21 Maxim
Clarus Therapeutics initiated with a Buy at Maxim
CRXT Clarus Therapeutics
/

+

CRXT Clarus Therapeutics
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.